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which binds to methylated regions of DNA to regulate tran-
scription, is expressed by hepatic stellate cells (HSCs) and is
required for development of liver fibrosis in mice. We investi-
gated the effects of MECP2 deletion from HSCs on their tran-
scriptome and of phosphorylation of MECP2 on HSC phenotype
and liver fibrosis. METHODS: We isolated HSCs from Mecp2–/y
mice and wild-type (control) mice. HSCs were activated in
culture and used in array analyses of messenger RNAs and long
noncoding RNAs. Kyoto Encyclopedia of Genes and Genomes
pathway analyses identified pathways regulated by MECP2. We
studied mice that expressed a mutated form of Mecp2 that
encodes the S80A substitution, MECP2S80, causing loss of
MECP2 phosphorylation at serine 80. Liver fibrosis was
induced in these mice by administration of carbon tetrachlo-
ride, and liver tissues and HSCs were collected and analyzed.
RESULTS: MECP2 deletion altered expression of 284
messenger RNAs and 244 long noncoding RNAs, including
those that regulate DNA replication; are members of the mini-
chromosome maintenance protein complex family; or encode
CDC7, HAS2, DNA2 (a DNA helicase), or RPA2 (a protein that
binds single-stranded DNA). We found that MECP2 regulates
the DNA repair Fanconi anemia pathway in HSCs. Phosphory-
lation of MECP2S80 and its putative kinase, HIPK2, were
induced during transdifferentiation of HSCs. HSCs from
MECP2S80 mice had reduced proliferation, and livers from
these mice had reduced fibrosis after carbon tetrachloride
administration. CONCLUSIONS: In studies of mice with
disruption of Mecp2 or that expressed a form of MECP2 that is
not phosphorylated at S80, we found phosphorylation of
MECP2 to be required for HSC proliferation and induction of
fibrosis. In HSCs, MECP2 regulates expression of genes required
for DNA replication and repair. Strategies to inhibit MECP2
phosphorylation at S80 might be developed for treatment of
liver fibrosis.Abbreviations used in this paper: APAP, N-acetyl-r-aminophen; BrdU,
bromodeoxyuridine; CCl4, carbon tetrachloride; ECM, extracellular matrix;
HSC, hepatic stellate cells; IL, interleukin; IPA, Ingenuity Pathway Anal-
ysis; KEGG, Kyoto Encyclopedia of Genes and Genomes; lncRNA, long
noncoding RNA; MCM, maintenance protein complex; MMP, matrix met-
alloproteinase; mRNA, messenger RNA; MTT, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide; PCA, principal components analysis;
qRT-PCR, quantitative reverse-transcription polymerase chain reaction;
SEM, standard error of the mean; a-SMA, a–smooth muscle actin; siRNA,
small interfering RNA; TGF, transforming growth factor; WT, wild type.Keywords: MCM; lncRNA; Myofibroblast; Epigenetic Factor.
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0016-5085
https://doi.org/10.1053/j.gastro.2019.07.029Iinflammation, fibrogenesis is an important contributor
to wound repair and regeneration. The purpose of fibro-
genesis is to form a temporary extracellular matrix (ECM)–
rich barrier known as granulation tissue, which serves to
maintain tissue integrity and prevent infection. Once
inflammation subsides and effective regenerative processesare underway, fibrogenesis subsides and gives way to
fibrolysis, leading to the natural breakdown of temporary
granulation tissue and its replacement with repaired
epithelial and endothelial structures. Where an injury and/
or inflammation persists or if regeneration is impaired, such
as in the aging organ, then fibrogenesis fails to subside and
instead promotes the net deposition and maturation of
fibril-forming collagen-rich ECM. In time, if unabated, non-
resolving fibrogenesis leads to the formation of highly
crosslinked mature scar tissue that distorts and perturbs
normal organ architecture and function. Liver fibrosis is a
common pathologic process associated with the majority of
chronic liver diseases and, in the absence of an effective
treatment for the underlying cause of liver damage, will
often progress to end-stage cirrhosis and/or hepatocellular
carcinoma.1,2 The relatively recent discovery that fibro-
genesis is highly dynamic, with the potential to both regress
and progress, was an important conceptual milestone, as
was the clinical observation made across multiple types of
liver disease that fibrosis can spontaneously regress upon
effective therapeutic removal of the causative agent. These
discoveries have stimulated new investigations into the
molecular mechanisms of fibrogenesis and have convinced
the pharmaceutical industry that fibrosis is an attractive and
tractable therapeutic target in chronic liver diseases.
A further conceptual milestone was the experimental
demonstration that, irrespective of cause of liver injury,
myofibroblasts are the central cellular drivers of collagen
deposition.1,3 Liver myofibroblasts are rare in uninjured
liver, but in response to damage and inflammation are
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
During development of liver fibrosis, hepatic stellate cells
differentiate into myofibroblasts. This process is regulated
by epigenetic events, including those controlled by the
methyl-CpG binding protein 2 (MECP2).
NEW FINDINGS
MECP2 regulates expression of mRNAs and long
noncoding RNAs in hepatic myofibroblasts, including
those that control DNA replication. MECP2 is
phosphorylated at S80; mutation of this amino acid
protects mice from toxin-induced liver fibrosis.
LIMITATIONS
This study was performed in mice and did not determine
whether MECP2 directly affects transcription of the
genes identified.
IMPACT
Phosphorylation of MECP2 affects its ability to regulate
gene expression and fibrosis. Strategies to inhibit
MECP2 might be developed for treatment or prevention
of liver fibrosis.
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Rgenerated chiefly from resident cells of mesenchymal line-
age, the major sources being hepatic stellate cells (HSCs)
and periportal fibroblasts.4 Upon hepatocellular damage,
peri-sinusoidal HSCs are triggered to undergo a complex
phenotypic conversion (or transdifferentiation) into a–
smooth muscle actin–positive (a-SMAþ), collagen-secreting
myofibroblasts.1–4 Where injury resolves, HSC-derived
myofibroblasts are either removed from the tissue by
apoptosis or may undergo a partial reversion of phenotype
to return to a non–collagen-expressing state.5 Experimental
in vivo studies strongly support the concept that myofi-
broblasts are required for fibrogenesis to take place and
that their subsequent removal is necessary for cessation of
fibrogenesis and a mechanistic switch to fibrolysis.
Furthermore, although HSCs are normally quiescent, upon
transdifferentiation, they enter the cell cycle and, in
response to paracrine and autocrine mitogens (eg, the
platelet-derived growth factor PDGF-BB), adopt a highly
proliferative and migratory state that serves to amplify and
spread the fibrogenic reaction.4 Hence, the complex events
that enable HSC transdifferentiation and the mechanisms by
which the cell adopts its proliferative and profibrogenic
behaviors are of major interest in the goal of therapeutic
targeting of liver fibrosis.
We previously proposed that HSC transdifferentiation is
under tight epigenetic control and identified the prototypic
methyl-DNA binding protein Mecp2 as being essential for
experimental liver fibrosis.6 Subsequently, a similar role for
Mecp2 has been described in the bleomycin model of lung
fibrosis and in the development of interstitial fibrosis in a
mouse model of myocardial infarction, and other reports
have confirmed profibrogenic functions for Mecp2 in myo-
fibroblasts from multiple tissue origins.7–9 In our earlier
studies, we focused on Mecp2 as a key transcriptional
repressor of the nuclear hormone receptor PPAR-g becausedown-regulation of PPAR-g is a necessary event for HSCs to
adopt a fully transdifferentiated myofibroblast state.6 Other
proposed targets of Mecp2 relevant to its role in fibrosis
include the tuberous sclerosis proteins TSC1 and TSC2,
which regulate fibroblast differentiation and proliferation;
the hedgehog receptor PTCH1 (Patched 1); HDAC6 (histone
deacetylase 6); DUSP5 (dual specificity phosphatase 5); the
Wnt pathway regulator SFRP4 (secreted frizzled-related
protein 4); transforming growth factor (TGF) b1–induced
a-SMA; and RASAL1 (RAS GTPase activating-like protein 1).
In this study, we used bulk transcriptome profiling to
determine that Mecp2 exerts broad influence over the
coding and noncoding transcriptional landscapes of the
HSC-derived myofibroblast and is required for the expres-
sion of transcripts that control DNA integrity and replica-
tion. Given the importance of these observations, we also
identified a site-specific phosphorylation event on the
Mecp2 protein that is required for its stimulation of HSC
proliferation and that, upon mutation, reduces the level of
toxin-induced liver fibrosis compared with that of wild-type
(WT) mice. This work therefore expands our understanding
of the mechanisms by which Mecp2 regulates myofibroblast
behavior and shows a regulated translational modification
of the protein that may be targeted for antifibrotic
purposes.Materials and Methods
Ethics
The authors hold appropriate licenses for animal experi-
ments, which were issued/approved by local ethics committee
and UK Home Office.Animal Strains and Experimental In Vivo Liver
Fibrosis Models
WT strain C57Bl/6 and Mecp2–/y mice (strain B6.129P2[C]-
Mecp2tm1.1Bird/J) were obtained from The Jackson Labora-
tory (Bar Harbor, ME). Mecp2S80A mice were a gift from Qiang
Chang, (University of Wisconsin, Madison, WI).10Acetaminophen (Paracetamol) Acute Injury
Eight-week-old male Mecp2S80A and WT littermate mice
were injected intraperitoneally with N-acetyl-r-aminophen
(APAP) at 500 mg/kg body weight. APAP (Sigma-Aldrich, St
Louis, MO) was dissolved in 0.6 mL of warm (37C) sterile
phosphate-buffered saline before injection. Animals were killed
at 4 hours after APAP administration, after which serum and
liver tissue were collected.Acute Carbon Tetrachloride Model
Eight- to 10-week-old male Mecp2S80A and WT littermate
mice were intraperitoneally injected with a single dose of a
carbon tetrachloride (CCl4)/olive oil mixture in a 1:1 (volume/
volume) ratio at 2 mL per gram of body weight. Tissues were
harvested at 24, 48, and 72 hours after CCl4 injection. At least 4
animals were used per treatment group.
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Mice were intraperitoneally injected twice weekly for 4
weeks with a mixture of CCl4/olive oil in a 3:1 (volume/vol-
ume) at 2 mL per gram of body weight. Tissues were harvested
at 24 hours after the final CCl4 injection.
Cell Isolation and Culture
Mouse hepatic stellate cells from C57Bl6 WT, Mecp2–/y, or
Mecp2S80A livers were isolated using sequential pronase/
collagenase digestion followed by density-gradient centrifu-
gation with Nycodenz (Axis Shield, UK) (11% over 16.5%) as
described by Mann et al.6 Two to 5 livers were pooled for
each HSC isolation and considered as n ¼ 1. Purity of mouse
HSC preparations was assessed by autofluorescence 1 day
after isolation and was found to be >97%. Isolation of he-
patocytes and Kupffer cells was performed as previously
described by Perugorria et al.11 Hepatocytes were cultured in
William’s medium E (Sigma-Aldrich) supplemented with 10%
fetal bovine serum. Mouse HSCs and Kupffer cells were
cultured on plastic in Dulbecco’s modified Eagle medium,
supplemented with 100 units/mL penicillin, 100 mg/mL
streptomycin, 2 mmol/L L-glutamine, and 16% fetal calf
serum. Cell cultures were maintained at 37C at an atmo-
sphere of 5% CO2. Freshly isolated HSCs (day 0) were
considered quiescent and were cultured in plastic dishes to
transdifferentiate into activated HSC (day 7 onward).Small Interfering RNA Transfection and
Hyaluronic Acid Quantification
Mouse WT HSCs were prepared from 3 separate iso-
lations. Primary mouse HSCs (1  106/well) were seeded in
6-well plates and transfected at day 5 with small interfering
RNA (siRNA) by using INTERFERin siRNA Transfection Re-
agent (Polyplus Transfection, Illkrich, France). The siRNAs
used were Stealth siRNA targeting Has2 (hyaluronan syn-
thase 2) messenger RNA (mRNA) or Stealth Negative Control
Duplex siRNA (Invitrogen, Waltham, MA). The final concen-
tration of siRNA was 50 nmol/L. The cells were allowed to
grow for 72 hours after transfection; then they were har-
vested and RNA isolated. Conditioned media was collected
for HA quantification using the Hyaluronan Quantikine
enzyme-linked immunosorbent assay kit (DHYAL0; R&D
Systems, Minneapolis, MN) per the manufacturer’s
instructions.
For quantitative reverse-transcription polymerase chain
reaction (qRT-PCR) analysis, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay, bromodeoxyur-
idine (BrdU) assay, coding-noncoding gene coexpression
network analysis, histology/immunohistochemistry, sodium
dodecyl sulfate/polyacrylamide gel electrophoresis, immuno-
blotting, preparation and sequencing of WT and S80Ki
whole-liver RNA samples, transcript quantification and dif-
ferential expression analyses, and microarray and computa-
tional analyses, see the Supplementary Materials and
Methods.
Statistical Analysis
Data are expressed as mean ± standard error of the mean
(SEM). P values were calculated by either analysis of variancewith Bonferroni post hoc test or by Student t test as
appropriate.Results
Mecp2 Regulates Transcripts Controlling
Myofibroblast DNA Replication and Integrity,
Metabolism, and Fibrogenesis
To determine the biochemical pathways under the con-
trol of Mecp2, we carried out a Mouse LncRNA Array v2.0
(8  60,000; Arraystar, Rockville, MD) RNA microarray
screen on primary WT and Mecp2–/y murine HSCs that had
undergone culture-induced myofibroblast trans-
differentiation. The rationale for selection of array rather
than RNA sequencing for our transcriptome analysis was a
desire to map Mecp2-regulated long noncoding transcripts
(lncRNAs) as well as mRNAs. Typically, lncRNAs are
expressed at considerably lower abundance than mRNAs
and can be overwhelmed and underreported by RNA
sequencing.12 Use of the sequence-specific probe hybridi-
zation approach of the microarray platform avoids this bias
and enables a broader coverage of transcripts to be quan-
tified. Figure 1A confirms the absence of expression of the
Mecp2 protein in 3 individual Mecp2–/y HSC-derived myo-
fibroblast lines used for transcriptome analysis. Figure 1B
shows a volcano plot and associated heatmap (right panel)
displaying 124 up-regulated and 160 down-regulated
mRNA species identified from the microarray as reporting
a 2-fold or greater change in expression between Mecp2–/y
and WT myofibroblasts (Supplementary Tables 1 and 2).
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway
analysis (Figure 1C) showed that with loss of Mecp2, there
is reduced expression of mRNAs encoding proteins involved
in DNA replication, cell cycle control, DNA damage response
(eg, Fanconi anemia pathway), and cytokine-chemokine re-
ceptor interactions. In contrast, up-regulated mRNAs in
Mecp2–/y myofibroblasts encode proteins involved in com-
plement and coagulation cascades, metabolism of linoleic
acid, arachidonic acid, glutathione, xenobiotics (cytochrome
P450s), and control of the renin-angiotensin system. In-
genuity Pathway Analysis (IPA) of the differentially
expressed genes further confirmed a role for Mecp2 in the
control of DNA replication by showing a number of genes
involved in the pathways that were down-regulated in
Mecp2–/y myofibroblasts (Figure 1D). Furthermore, IPA
analysis also shows a major role for Mecp2 in the overall
epigenetic/transcriptional state of chromatin in myofibro-
blasts, with histones H3 and H4 as well as RNA polymerase
II identified as the central targets affected by the changes in
gene expression in Mecp2–/y myofibroblasts (Supplementary
Figures 1 and 2). To validate these data, we randomly
selected transcripts from the top 25 most overexpressed
and underexpressed genes in Mecp2–/y myofibroblasts for
qRT-PCR analysis (Figure 2A). Has2, Myl7 (myosin light
chain 7), and desmin transcripts were validated as under-
expressed relative to the WT; by contrast, a fourth tran-
script (aggrecan) failed validation (Supplementary
Figure 1.Mecp2 regulates the transcripts controlling myofibroblast DNA replication, cell cycle and integrity, metabolism, and
fibrogenesis. (A) Western blot for Mecp2 in HSCs fromWT orMecp2–/ymice. Schematic showing the samples used for lncRNA
microarray and RNA microarray. (B) Volcano plot and heatmap displaying results of mRNA microarray performed on activated
HSCs isolated from 3 control and 3 Mecp2–/y mice. (C) Representation of the groups with 2-fold or greater change in gene
expression after the KEGG pathway enrichment analysis. (D) Top significantly enriched canonical pathway identified by IPA,
showing cell cycle control of chromosomal replication. Blue nodes signify down-regulated gene Mecp2–/y fibroblasts; red
signifies up-regulation. Symbol shapes signify the nature of the encoded protein, and unshaded symbols signify genes
relevant to the pathway but not differentially expressed in our data set.
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15], Tnxb [tenascin XB], Sepp1 [selenoprotein P], and Ostn
[osteocrin]) selected from the heatmap of overexpressed
transcripts were validated by qRT-PCR (Supplementary
Figure 3B). We conclude that the observed de novo
expression of Mecp2 protein that occurs early in HSC
transdifferentiation affects the expression of approximately
280 protein-coding transcripts that influence key regulatory
pathways relevant to fibrosis.Mecp2 Regulates DNA Replication and Repair
Systems
We previously observed that myofibroblasts derived
from Mecp2–/y HSCs are difficult to establish in culture, and
there are many reports documenting the pro-proliferative
properties of Mecp2 in HSCs and other fibroblastlineages.13–16 It was therefore of particular interest that
KEGG pathway analysis highlighted a role for Mecp2 in the
control of DNA replication (Figure 1C). IPA analysis of these
data shows that a number of down-regulated genes in
Mecp2–/y HSCs are in the DNA damage and DNA replication
pathways (Figure 1D). Closer interrogation of the array data
showed reduced expression levels of several subunits for
the minichromosome maintenance protein complex (MCM),
which is a DNA helicase essential for DNA replication
(Figure 2B, left panel). In addition, Cdc7 (cell division cycle
7-related protein kinase), a kinase regulator of MCM, was
also expressed at reduced levels, as was a second DNA
helicase, Dna2 (DNA replication adenosine triphosphate–
dependent helicase/nuclease) and the single-stranded
DNA-binding protein Rpa2 (replication protein A2)
(Figure 2B). Given the critical role of the Mcm complex in
DNA replication, we validated these data by qRT-PCR, which
1402 Moran-Salvador et al Gastroenterology Vol. 157, No. 5
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subunits in Mecp2–/y HSCs (Supplementary Figure 4A).
Similarly, qRT-PCR confirmed reduced expression of mRNAs
encoding PolD1 (polymerase delta 1), Dna2, and Rpa2 in
Mecp2-deficient cells (Supplementary Figure 4B). To show
the relevance of these findings to HSC transdifferentiation,
MCM2, MCM5, and PolD1 proteins were all induced at an
early stage of HSC transdifferentiation (culture day 2) and in
concert with induction of CCNA2 (cyclin A2), which pro-
motes transition through G1/S and G2/M, and the DNA
polymerase processivity factor PCNA2 (proliferating cell
nuclear antigen 2), which is a marker for DNA replication
(Figure 2C). A further striking observation was an apparent
role for Mecp2 in the control of genes involved in the Fan-
coni anemia pathway, which play a fundamental role in DNA
repair responses. IPA analysis showed that multiple genes in
this pathway display reduced transcript expression in
Mecp2–/y HSCs (Figure 2D, down-regulated genes shown in
blue), and random selection of 3 of these genes (Eme1
[essential meiotic structure-specific endonuclease 1], Brip1
[BRCA1-interacting protein 1], and Rad51) provided qRT-
PCR validation of diminished expression (Supplementary
Figure 4C).
As an exemplar for the potential for using the Mecp2
transcriptome map to identify novel regulators of liver
fibrosis, we selected Mecp2-regulated Has2 for further
investigation. We confirmed that Has2 mRNA is highly
expressed in HSC-derived myofibroblasts relative to Kupffer
cells and hepatocytes (Figure 2E). Furthermore, Has2 tran-
script expression is elevated during culture-induced HSC
transdifferentiation, but by contrast, its functionally related
family members Has1 and Has3 were transcriptionally
down-regulated (Figure 2F). Induction of Has2 protein was
observed to occur with similar kinetics as Col1A1 (type IA1
collagen) and a-SMA; in addition, immunoblotting for the
HA receptor CD44 showed a similar de novo induction
occurring within 2 days of culturing (Figure 2G). It has
previously been reported that the hyaluronan synthase
isoform Has2 plays a profibrogenic function in the lung;
however, its role as a profibrogenic factor in HSC was not
determined.17 Therefore, we used siRNA-mediated knock-
down of Has2 in transdifferentiating HSC and observed an=
Figure 2.Mecp2 regulates DNA replication and repair systems;
playing the results of mRNA microarray performed on activated H
most up-regulated and down-regulated genes are shown. Blue d
(B) Heatmap displaying the most down-regulated genes with a f
MCM2, MCM5, POLD1, PCNA, CCNA2, and GAPDH in WT HSC
network of focus genes that are downstream targets of differential
regulated in Mecp2–/y myofibroblasts; red signifies up-regulation
unshaded symbols signify genes relevant to the pathway but not
fromHSCs, Kupffer cells (KC), andhepatocytes (Hep). (F)mRNA le
culture. (G) Western blot for COL1A1, HAS2, the receptor CD44, a
(H) Schematic showing the silencingexperiment:HSCswere cultu
siRNA (1þ 3), single Has2 targeting siRNA (3) or a negative contr
Has2,MMP9,MMP13, and transforming growth factorb in contro
± SEM. Statistical significance was determined by ANOVA; *P< .
SMA, and GAPDH and (J) HA enzyme-linked immunosorbent asassociated 50% reduction in expression of TGFb1 and
blunted expression of transcripts for the ECM modulators
matrix metalloproteinase (MMP) 9 and MMP13 (Figure 2H).
We further observed a reduction in Col1A1 and a-SMA
expression (Figure 2I), as well as a reduction in HA pro-
duction in HSCs transfected with Has2 siRNA (Figure 2J).
These data indicate that Mecp2 can extend its control over
fibrogenesis beyond that of its immediate target genes.Mecp2 Is a Regulator of the Noncoding
Transcriptome
We next focused our attention on the potential for
Mecp2 to influence the HSC lncRNA landscape using the
array data from our analysis of WT and Mecp2–/y cells. A
volcano plot of lncRNAs detected in the array and subse-
quent heat mapping of differentially regulated transcripts
showed that absence of Mecp2 alters the expression of 244
lncRNAs, of which 161 species were up-regulated and 83
were down-regulated relative to the WT (Figure 3A and
Supplementary Tables 3 and 4). lncRNAs can be classified
according to their genomic location. Mecp2 had the greatest
influence on lncRNAs derived from intragenic (so-called
lincRNAs) sense and antisense overlapping localities and
had a lesser effect on lncRNAs classified as intergenic or
bidirectional (Figure 3B). Further genomic analysis showed
that Mecp2 influences the expression of lncRNAs that are
classified according to their association with known and
unknown protein coding genes (Figure 3C). From a focused
heatmap of the 50 most up- and down-regulated lncRNAs in
Mecp2–/y cells, (Figure 3D), we identified the down-
regulated transcript uc008hgf as being in close physical
association with the Acta2 (a-SMA) locus (Supplementary
Figure 5). qRT-PCR confirmed reduced expression of
uc008hgf and Acta2 in Mecp2–/y HSCs (Supplementary
Figure 5). Coding-to-noncoding coexpression analyses and
IPA analysis from the array data identified Mecp2-regulated
mRNA-lncRNA networks, including systems controlling DNA
metabolic processes, innate immunity, protein activation
cascades, and cell cycle (Figure 3E and Supplementary
Figure 6), thus reaffirming a regulatory role for Mecp2 in
DNA replication and repair systems.Has2 is involved in HSC transdifferentiation. (A) Heatmap dis-
SCs isolated from 3 control and 3Mecp2–/y mice. The top 50
enotes down-regulation; red, up-regulation; white, unchanged.
undamental role in DNA repair responses (C) Western blot for
s after 0, 2, 5, and 8 days in culture. (D) IPA was used to form a
ly expressedmRNAs. Blue nodes signify that a genewasdown-
. Symbol shapes signify the nature of the encoded protein, and
differentially expressed in our data set. (E) mRNA level of Has2
vels ofHas2,Has1, andHas3 inHSCsafter 0, 2, 5, and8days in
-SMA, and GAPDH in HSCs after 0, 2, 5, and 8 days in culture.
red for 5days, then transfectedwith a cocktail ofHas2 targeting
ol (Con) and harvested 48 hours later on day 7. mRNA levels of
l andHas2 siRNA–transfectedHSCs. Error bars representmean
05, **P< .01, ***P< .001. (I) Western blot for Col1A1, CD44, a-
say in HSCs transfected with Has2 siRNA (as in H).
Figure 3.Mecp2 is a regulator of the noncoding transcriptome. (A) Volcano plot and heatmap displaying results of lncRNA
microarray performed on activated HSCs isolated from 3 control and 3 Mecp2–/y mice. (B) Schematic showing the lncRNAs
classified according with their genomic location. (C) Schematic showing the lncRNAs according to their association with
known and unknown protein coding genes. (D) Heatmap displaying results of lncRNA microarray performed on activated HSCs
isolated from 3 control and 3 Mecp2–/y mice. The top 50 most up-regulated and down-regulated lncRNAs are shown. Blue are
down-regulated; red, up-regulated; white, unchanged. (E) IPA was used to form a network of focus genes that are downstream
targets of differentially expressed lncRNAs. Blue nodes show down-regulated genes in Mecp2–/y myofibroblasts, red nodes
are up-regulated. Symbol shape signifies the nature of the encoded protein, and unshaded symbols signify genes relevant to
the pathway but not differentially expressed in our data set.
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RMecp2 Phosphorylation Is Required for Hepatic
Stellate Cell Proliferation and Collagen
Expression
With the longer-term aim of designing molecular stra-
tegies for therapeutically manipulating the fibrogenic activ-
ities of Mecp2, we examined its posttranslational
modification by site-specific phosphorylation. Mass spec-
trometry analysis has identified at least 8 sites of phos-
phorylation, including S80, T148/S149, S164, S229, S399,
S421, and S424.18 Mutations at S80 and S421/S424 have
been studied in neurons and shown to modify Mecp2 func-
tion.18 Of particular importance was the discovery that
phosphorylation at the S80 residue is important for DNA
binding, such that mutating S80 to alanine reduced the
affinity of Mecp2 for multiple target gene promoter
sequences.10 Immunoblotting for Mecp2 and its phospho-
modified forms was carried out across a time course of
culture-induced HSC transdifferentiation. As anticipated
from our previous work, Mecp2 controls an epigenetic
pathway that promotes myofibroblast transdifferentiation
and fibrosis.6 Mecp2 was absent in freshly isolated (day 0)
HSCs but was induced during the early (initiation) phase of
transdifferentiation, appearing at day 2 of culture, and this
expression persisted throughout further culturing
(Figure 4A). Of note, the molecular weight of Mecp2 detected
in HSCs was approximately 70 kDa, which has previously
been reported as the weight of the slower-migrating phos-
phorylated form of the protein.19 Antibodies recognizing
phosphorylation at S80 (pMecp2S80) and S421 (pMecp2S421)
also detected a protein of approximately 70 kDa that was
absent in freshly isolated HSCs and appeared at day 2 of
culture. Furthermore, we also detected at the same time
point induction of HIPK2 (homeodomain-interacting protein
kinase 2), which is reported to bind to Mecp2 and phos-
phorylate it at its S80 residue.20 These data encouraged us to
examine the role of pMecp2S80 in HSCs using primary cells
isolated from digested livers of mutant Mecp2S80A knock-in
(S80A) mice. Although we were able to establish Mec-
p2S80A HSC lines, they were morphologically observed to be
more rounded (ie, less activated) and were slower growing
than WT lines (Supplementary Figure 7); the reduced pro-
liferative rate was confirmed by BrdU incorporation
(Figure 4B), and MTT assays were carried out across a time
course of transdifferentiation (Figure 4C). Moreover, S80A
HSCs were impaired for expression of Mcm5 transcript and
protein (Figure 4D) and displayed diminished expression of
CCNA2 and Brip1 (Figure 4E). In addition, day 8 S80A HSCs
expressed considerably less cyclin D1 and E1 (Figure 4F).
Given our previous observation that Mecp2 is required for
HSC expression of fibrogenic genes, we next determined if
phosphorylation at S80 was required for this function. As
shown in Figure 4G, S80A HSCs consistently expressed
reduced levels of transcripts for COL1A1 and displayed a
delay in maximal expression of a-SMA; however, induction
of TIMP1 (tissue inhibitor of metalloproteinase-1) mRNA
was no different between S80A and WT HSC. These data
suggest that S80 phosphorylation selectively modulates a
subset of the fibrogenic characteristics of HSC.Mecp2-S80 Phosphorylation Is Required for
Toxin-Induced Liver Fibrosis
We were next interested to determine whether modu-
lation of HSC behavior by S80 phosphorylation affects liver
fibrosis. Before determining a role in fibrosis, we asked if
the S80A mutation has any effect on the normal physiology
and response of the liver to acute toxic injury. Histologic
examination of S80A livers did not show any gross anatomic
abnormalities; however, we did note a mild steatosis, which
was confirmed by Oil Red-O staining (Figure 5A). This
observation was followed up with transcriptomic
sequencing of uninjured WT and S80A Knockin livers, which
showed segregated clustering of 2 groups, as determined by
using principal component analysis (PCA) (Figure 5B),
suggesting that S80A livers have phenotypic differences at
baseline. A heatmap generated from the transcriptome
analysis shows 31 up-regulated and 233 down-regulated
RNA species reporting a 2-fold or greater change in
expression between S80A compared with WT control livers
(Figure 5C and Supplementary Table 5). We observed no
gross differences in the response of S80A mice to sublethal
paracetamol intoxication (Figure 5D), although examination
of inflammatory gene expression did show unanticipated
defects in the induction of tumor necrosis factor a, inter-
leukin (IL) 1b, IL-6, and CXCL2 (chemokine ligand 2) in
paracetamol-injured S80A livers (Figure 5E). Given these
effects of the S80A mutation on liver physiology and
response to acute injury, we reassessed the cellular
expression of MeCP2 in mouse liver. MeCP2 protein was
barely detectable by Western blotting in whole liver but was
abundantly expressed in HSCs (Supplementary Figure 8A);
this result supports previous reports from our group and
other investigators that hepatocytes express very low levels
of MeCP2, whereas activated HSCs abundantly express the
protein.21–23 Similar to injury with paracetamol, acute
damage with CCl4 was similar between S80A and the WT
based on measurement of alanine aminotransferase
(Figure 6A). Moreover, analysis of a-SMA expression as a
surrogate for HSC transdifferentiation showed a similar
acute fibrogenic response between S80A and the WT
(Figure 6B). By contrast, chronic injury with CCl4 suggested
partial protection of S80A mice from development of
fibrosis as determined by Picrosirius red staining and
morphologic quantification of cross-linked collagens
(Figure 6C), although no difference was observed in the
amount of a-SMA staining (Figure 6D). This protective effect
was mirrored by reduced hepatic expression of COL1A1, a-
SMA, IL-6, MMP2, and TIMP1 (Figure 6E). In addition, we
measured improved liver function (aspartate aminotrans-
ferase and alanine aminotransferase) and liver/body weight
measurements as outputs of liver health in the S80A mutant
mice (Supplementary Figure 8B and C). Of note, similar
chronic CCl4 challenge in Mecp2
S421A/S424A mice showed no
effect on fibrosis or liver function (data not shown). We
conclude that site-specific phosphorylation of Mecp2 at its
S80 residue is required for a robust fibrogenic reaction to
iterative liver damage but is not required for normal liver
physiology or for the wound-healing response to acute liver
Figure 4.Mecp2 phosphorylation at S80 is required for HSC proliferation and collagen expression. (A) Western blot for Mecp2,
pMecp2S80, pMecp2S421, HIPK2, a-SMA, and GAPDH in HSCs after 0, 2, 5, and 8 days in culture. (B) Proliferation assay: BrdU
incorporation was measured in WT and Mecp2S80A HSCs after 0, 2, 5, and 8 days in culture. (C) Viability assay: reduced MTT
was measured in Mecp2S80A HSCs (compared with WT HSCs) after 0, 2, 5, and 8 days in culture. (D) mRNA level of Mcm5
quantified by qRT-PCR in WT and Mecp2S80A HSCs after 0, 2, 5, and 8 days in culture. Western blot for MCM5 and b-actin in
WT and Mecp2S80A HSCs after 8 days in culture. (E) mRNA level of CCNA2 and BRIP1 in WT and Mecp2S80A HSCs after 0, 2,
5, and 8 days in culture. (F) Western blot cyclin D1 and E1 in WT and Mecp2S80A activated HSCs (8 days in culture). (G) Col1A1,
a-SMA, and TIMP1 quantified by qRT-PCR in WT and Mecp2S80A HSCs after 0, 2, 5, and 8 days in culture. Error bars represent
mean ± SEM. Statistical significance was determined by ANOVA or Students t test; *P < .05, ** P < .01, *** P < .001. denotes
a trend with P < .1.
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on fibrosis, we performed transcriptomic sequencing of
CCl4-injured livers. Sequencing data from 2 groups were
normalized and used to generate a PCA plot, which showed
clear phenotypic differences between the WT and S80A
(Figure 7A). Interrogation of the sequencing data showed
reduced expression of 116 genes and up-regulation of 306
genes in S80A livers compared with the WT (Figure 7B and
Supplementary Table 6). IPA analysis of differentially
expressed genes in S80A-injured livers showed similar
networks to those identified in Mecp2–/y myofibroblasts,
particularly pathways involving histones H3 and H4, extra-
cellular signal–regulated kinases 1 and 2, and RNA poly-
merase II (Figure 7C and D and Supplementary Figures 1
and 2). These data suggest a role for S80 phosphorylationin controlling Mecp2-mediated regulation of chromatin
structure and gene transcription as well as mitogen-
activated protein kinase signaling cascades in hepatic
myofibroblasts and liver fibrosis.Discussion
Experimental in vivo studies in mice across multiple
organ systems (liver, lung, and heart) have identified Mecp2
as an important epigenetic profibrogenic factor.6,14 These
data are supported by in vitro studies suggesting that
Mecp2 promotes the fibrogenic characteristics of fibroblasts
and myofibroblasts from numerous tissues.7–9 An exception
to these observations was a recent report of Mecp2 sup-
pressing the fibrogenic characteristics of human dermal
Figure 5.Mecp2S80 phosphorylation causes baseline difference in gene expression in uninjured liver and is required for
paracetamol-induced liver fibrosis. (A) Liver sections showing neutral triglycerides and lipids staining with Oil Red O from WT and
Mecp2S80A mice. (B) Gene expression variances betweenWT andMecp2S80A uninjured livers displayed as PCA plot of scaled log2-
transformed transcript counts. (C) Heatmap displaying results of transcriptome sequencing carried out using 3 uninjured livers from
WTandMecp2S80Amice. The geneswith greater than 2-fold change and significant toP< .01 are shown.Green are down-regulated
in Mecp2S80A; red, up-regulated; black, unchanged. (D) Liver morphology shown with H&E staining fromWT and Mecp2S80A mice,
control or treatedwithparacetamol.Photomicrographsareat originalmagnificationof100. (E)mRNA levelsof tumornecrosis factor
a, IL-1b, IL-6, andMIP2a/CXCL2 quantified by qRT-PCR inWT andMecp2S80Amice, control or treated with paracetamol (n¼ 8 per
group). Error bars in relevant panels represent mean ± SEM. Statistical significance was determined by ANOVA or Student t test;
*P < .05, ** P < .01, *** P < .001. signif diff, significantly different.
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impact on fibrosis.7 Hence, a consensus is emerging that in
the majority of organs, Mecp2 promotes fibrosis through its
activities in the fibroblast/myofibroblast. Of relevance to
the functions of MeCP2 in liver fibrosis, expression of
MeCP2 is found at very low levels in healthy liver,21,22 and
this was confirmed in our study. By contrast, MeCP2
expression is elevated in fibrotic liver where its expression
is predominantly localized to liver myofibroblasts.23 Here,
we shed further light on the degree to which Mecp2 exerts
its influence on the phenotype of HSC-derived myofibro-
blasts by discovering that it modulates the expression of at
least 529 transcripts, comprising 284 mRNAs and 244
lncRNAs. Differential transcript expression in Mecp2–/y HSCs
included up- and down-regulation in both mRNA and
lncRNA families. Although Mecp2 was originally described
as a gene silencer,24,25 more recent studies have described
cell-type–specific functions for Mecp2 and an unexpected
role as a gene activator.26–28 These dual opposing functions
of Mecp2 are at least in part explained by the activities of its
numerous coregulators; for example, CREB (cAMP response
element binding) enhances transcription, whereas HDAC/
Sin3A (histone deacetylase/paired amphipathic helix pro-
tein) complexes that assemble with Mecp2 at the promoters
of repressed genes are known to have potent suppressive
activities on transcription.29 Additionally, Mecp2 can influ-
ence gene expression via its role in chromatin organization
and architecture, which is further indicated in the data
presented in this report.30–32 We have also described how
Mecp2 can indirectly influence transcription by modulating
the expression of other epigenetic factors such as ASH1
(histone-lysine N-methyltransferase) and EZH2 (enhancer
of zeste homolog 2) that associate with regulatory regions
of profibrogenic genes.6,33 Furthermore, as we have
discovered in this study, Mecp2 has a regulatory influence
on lncRNAs, which, in large part, exert their regulatory ef-
fects via chromatin remodeling activities. These alternative
mechanisms to the DNA-binding functions of Mecp2 high-
light an important limitation of the work presented here to
be addressed in future: our available data cannot distin-
guish the degree to which Mecp2 controls the HSC tran-
scriptional landscape through its direct actions at gene
promoters vs its various indirect modes of action. A further
limitation is the use of cultured HSCs, which may not
accurately recapitulate changes in gene expression associ-
ated with HSC transdifferentiation in vivo.34 However, a
danger with isolating transdifferentiated HSCs from the
damaged liver is the degree to which subsets of phenotyp-
ically distinct cells are preferentially recovered by the=
Figure 6.Mecp2S80 phosphorylation is required forCCl4-induced l
and 72 hours after CCl4/olive oil injection in WT and Mecp2
S80A
showing a-SMAstaining fromWTandMecp2S80Amice treatedwith
a-SMA staining (n ¼ 6 per group). (C, D) Liver sections showing co
p2S80Amice treated with chronic CCl4 or olive oil vehicle. Associate
Redora-SMAstaining.Photomicrographsareatoriginalmagnificat
TIMP1 quantified by qRT-PCR in WT and S80A mice treated wit
represent mean± SEM. Statistical significance was determined by
Significantly different.isolation protocol. Furthermore, this may be exacerbated in
Mecp2–/y livers where fibrosis is minimal; because Mecp2–/y
HSCs have an altered phenotype, they are more challenging
to identify and isolate from the damaged liver. Despite these
limitations, by comparing the transcriptional landscapes of
WT and Mecp2–/y HSCs, we have discovered, to our
knowledge, genes that were previously unrecognized as
Mecp2 regulated and that to date have not been studied in
the context of liver fibrosis yet functionally can be linked to
the fibrotic process.
HSCs are typically quiescent, but upon trans-
differentiation they will proliferate under the stimulation of
a variety of mitogenic factors such as PDGF, IL-6, glucose,
and leptin.4 Initiation of DNA replication is a key regulatory
process in HSC transdifferentiation and, as in all prolifer-
ating cells, requires “melting” of double-stranded DNA at the
origin recognition complex. A key role for the origin
recognition complex is to load the MCM2–7 replicative
helicase onto the DNA, which, upon completion, results in
assembly of the pre-replicative complex that licenses pro-
gression to the S phase.35 MCM proteins are required at
abundant levels in proliferative cells to ensure accuracy of
DNA replication and to protect against replicative stress
during the S phase.36 Indeed, in the absence of a full com-
plement of MCM proteins, genome integrity is lost.37 We
show here that MCM proteins are induced with HSC trans-
differentiation from either low or, in the case of MCM5,
undetectable levels of expression in quiescent HSCs. To our
knowledge, we have for the first time described Mecp2 as
being required for expression of multiple Mcm gene tran-
scripts. These findings suggest a vital role for Mecp2 as a
regulator of DNA replication and integrity and explain
numerous reports of associations of Mecp2 with cell pro-
liferation.38,39 We also report that Mecp2 regulates Has2,
which is the major isoform of the HASs expressed in
mesenchymal cells where it is responsible for production
HA, a key component of the ECM and a modulator of
collagen deposition.40 HAS2 has also been implicated as a
regulator of cell senescence and proliferation, with sup-
pression of HAS2 in tumor cells arresting the cell cycle in
the G1 phase.41 More recently, Has2 has been described as
promoting the invasive phenotype of fibrogenic lung fibro-
blasts and, when experimentally down-regulated in these
cells, promotes senescence and resolution of pulmonary
fibrosis.17 We found that HAS2 and HA receptor CD44 are
induced during HSC transdifferentiation. Of note, CD44
protein expression was undetectable in quiescent HSCs and
was abundantly expressed at day 2 of culture, which coin-
cided with abundant induction of MCM2 and MCM5 proteinsiver fibrosis. (A) Alanine transaminase (ALT) assessment at 24, 48,
mice treated with acute CCl4 or vehicle. (B) Histologic sections
acuteCCl4. Graph shows the percentage of the area positive for
llagen staining (Picrosirius Red) and a-SMA from WT and Mec-
d graphs show the percentage of the area positive for Picrosirius
ionsof40. (D)mRNA level ofCOL1A1,a-SMA, IL-6,MMP2, and
h olive oil vehicle or chronic CCl4. Error bars in relevant panels
ANOVA or Student t test; *P<.05, **P<.01, ***P<.001. Signif diff,
Figure 7.Mecp2S80 phosphorylation regulates gene expression in CCl4-induced liver fibrosis. (A) Gene expression variances
between WT and Mecp2S80A fibrotic livers displayed as PCA plots of scaled log2-transformed transcript counts. (B) Heatmap
displaying results of transcriptome sequencing carried out using 3 CCl4-injured livers from each of the WT and Mecp2
S80A
mice; genes with greater than 2-fold change and significant to P < .01 are shown. Green indicates negative values (down-
regulated in Mecp2S80A); red, positive (up-regulated in Mecp2S80A); black, unchanged. (C, D) IPA was used to form a network of
focused genes that are downstream targets of differentially expressed RNAs. Blue nodes show down-regulated genes in
Mecp2S80A CCl4-injured liver; red nodes are up-regulated. Symbol shapes signify the nature of the encoded protein (see
Supplementary Figures 1 and 2 for shape information), and unshaded symbols signify genes relevant to the pathway but not
differentially expressed in our data set. signif diff, significantly different.
1410 Moran-Salvador et al Gastroenterology Vol. 157, No. 5
BASIC
AND
TRANSLATIONAL
LIVERand cyclin A2 (CCNA2), the latter being required for the G2/
M phase transition. We therefore propose that Mecp2 reg-
ulates initiation and progression of HSC DNA replication via
2 distinct pathways. Molecular targeting of Mecp2 may
therefore offer an attractive approach for suppressing the
proliferative and invasive behavior of fibrogenic cells. To
this end, we were encouraged by the finding that HSCs
lacking the ability to phosphorylate the S80 residue of
Mecp2 were defective for expression of MCM5 and dis-
played impaired proliferation. Because S80A mutant micewere able to mount a normal acute wound repair response
to toxic liver injury yet were at least partially protected
from fibrosis in the context of chronic liver damage, tar-
geting translational modification events on Mecp2 may offer
a therapeutic strategy in fibrosis. As previously mentioned,
in the absence of fibrosis, MeCP2 is expressed in the liver at
low to negligible levels. Moreover, MeCP2 is reported to be
expressed in hepatocytes, and specific deletion of epithelial
MeCP2 promotes steatosis.42 We also observed mild stea-
tosis in the livers of S80A knockin animals and elevated
November 2019 Mecp2 Controls Myofibroblast Transcriptome 1411expression of inflammatory mediators in S80A knockin liver
in response to acute injury with paracetamol. Hence,
although S80 phosphorylation in myofibroblasts offers an
intriguing therapeutic target, the same modification may be
important for baseline metabolic functions of MeCP2 in
hepatocytes, and this would need to be considered if S80 or
its kinase HIPK2 were to be developed for therapeutic
applications.
In summary, Mecp2 helps orchestrate widespread
changes in the RNA landscape that convert the quiescent
HSC into fibrogenic cells and is required for the expression
of genes that regulate entry and progression of HSC DNA
replication. Because site-specific phosphorylation of Mecp2
contributes to these events and is a modulator of liver
fibrosis, manipulation of enzymes regulating Mecp2 phos-
phorylation has potential for therapeutic targeting.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at https://doi.org/10.1053/
j.gastro.2019.07.029.ReferencesBA
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Supplementary Materials and Methods
Quantitative Reverse-Transcription Polymerase
Chain Reaction Analysis
Total RNA was purified from isolated cells by using the
Total RNA purification kit (Qiagen, Manchester, UK)
following the manufacturer’s instructions. One microgram of
total RNA was DNAse treated (Promega, Madison, WI) and
used as a template to generate complementary DNA by
using a random hexamer primer (p[dN]6) and MMLV
reverse transcriptase (Promega). Primer sequences are
included in Supplementary Table 1. SYBR Green qRT-PCR
reactions were performed in a total volume of 13 mL con-
taining 20 ng of complementary DNA template, 6.5 mL of
SYBR Green JumpStart Taq ReadyMix (Sigma-Aldrich), and
20 pmol of forward and reverse primers (Supplementary
Tables 1–3). The PCR reaction was carried out on a 7500
Fast Real-Time PCR System (Applied Biosystems, Warring-
ton, UK) with the following parameters: 1 cycle at 95 C for
10 seconds followed by 40 cycles at 95C for 10 seconds,
57C0–60C (for primer pair–specific annealing tempera-
tures, see Supplementary Table 1) for 30 seconds, and
finally 72C for 30 seconds. Melt curve analysis was used to
confirm presence of a single PCR product. All reactions were
normalized to b-actin or GAPDH internal control, and rela-
tive level of transcriptional difference calculated by using
the following equation: (1/[2A]) 100.
MTT Assay
Cellular viability was determined by using the MTT
assay where day 2, 3, 5, and 8 primary HSCs from WT or
MeCP2S80A livers were seeded onto 24-well plates and
treated with MTT (5 mg/mL, Sigma) for 1.5 hours. Cells
were rinsed with phosphate-buffered saline and fixed in
isopropanol; the plates were shaken at 240 revolutions for
minute for 10 minutes. The absorbance was measured at
570/620 nm in a SpectraMax (Grodig, Austria) plate
reader.
BrdU Assay
Cells were labeled with BrdU in fresh cell media con-
taining 16% fetal bovine serum for 18 hours. Cell prolifer-
ation was determined by BrdU incorporation, following the
manufacturer’s instructions for the Cell Proliferation
enzyme-linked immunosorbent assay (Roche, Basel,
Switzerland).
Coding-Noncoding Gene Coexpression Network
Analysis
To identify possible biological functions, we performed a
coding-noncoding gene coexpression network analysis1 of
the coexpressed lncRNAs related to genes. The coexpression
matrix was calculated with the Perl package “Statistics
Basic,” and the “correlation” function was filtered to include
only the interactions for which the absolute value of the
Pearson correlation coefficient r was > 0.99.2,3 The coding-
noncoding coexpression network was visualized with the
bioinformatics software Cytoscape.4
Histology and Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections were
stained with 0.1% Picrosirius red and H&E with established
protocols. Immunohistochemistry was performed on
deparaffinized sections, and endogenous peroxidase activity
was blocked by using 0.6% hydrogen peroxide/methanol
solution. Heat-mediated antigen retrieval was achieved by
using antigen unmasking solution. Endogenous avidin and
biotin were blocked with an Avidin/Biotin Blocking Kit
(Vector Laboratories, Burlingame, CA), and nonspecific
binding was blocked by using 20% swine serum for 30
minutes; then a-SMA 1:1000 (F3777; Sigma-Aldrich) was
incubated overnight at 4C. The next day, slides were
washed and incubated with biotinylated goat anti-
fluorescein 1:300 (BA-0601, Vector Laboratories, Peter-
borough, UK) for 1 hour. Slides were washed and incubated
with Vectastain Elite ABC Reagent for 45 minutes. Staining
was visualized by using a 3,30-diaminobenzidine tetra hy-
drochloride peroxidase substrate kit and counterstained
with Mayer’s hematoxylin before mounting. Slides were
analyzed at 20 magnification with a Nikon (Tokyo, Japan)
Eclipse Upright microscope and NIS-Elements BR analysis
software (Nikon). Ten random fields of liver were analyzed
per section. All images presented are at original magnifica-
tions of 100, and scale bars equal 100 mm unless other-
wise stated.
Oil Red O Staining
Fifteen-micrometer frozen sections were fixed in Baker’s
formol-calcium, washed in distilled water, and then incubated
with 60% isopropanol for 5 minutes. Sections were then
incubated in Oil Red O solution for 20 minutes, transferred to
60% isopropanol for 5 minutes, washed with distilled water,
and then mounted with Kaiser’s glycerol-gelatin.
Sodium Dodecyl Sulfate–Polyacrylamide Gel
Electrophoresis and Immunoblotting
Whole-cell extracts were prepared, and protein concen-
tration of samples was determined by using Bio-Rad DC
Protein Assay (Bio-Rad, Watford, UK). Proteins were sepa-
rated on 10% or 12% sodium dodecyl sulfate poly-
acrylamide gel and transferred onto a nitrocellulose
membrane in buffer containing 25 mmol/L Tris, 192 mmol/
L glycine, and 20% methanol. Blots were blocked with Tris-
buffered saline/Tween 20 (0.1%) containing 5% milk pro-
tein before overnight incubation with primary antibodies:
rabbit anti-MeCP2 (C15410052; Diagenode, Liege, Belgium),
MCM2 (D7G11; Cell Signaling Technology, Danvers, MA),
MCM5 (ab75975; Abcam, Cambridge, UK), PolD (ab186407,
Abcam), CCNA2 (ab38, Abcam), PCNA (ab2426, Abcam),
Col1A1 (AB765P; Millipore, Billerica, MA), a-SMA (A5228,
Sigma-Aldrich), HAS2 (sc365263; Santa Cruz Biotechnology,
Dallas, TX), CD44 (AF6127, R&D Systems), pMeCP2 S80
(AP3595a; Abgent, San Diego, CA), pMeCP2 S421 (PA5-
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35396; Thermo Fisher Scientific, Waltham, MA), HIPK2
(5091, Cell Signaling Technology), and rabbit anti-GAPDH
(ab22555, Abcam). Secondary antibody anti-rabbit (7074S,
Cell Signaling Technology) and anti-mouse (A4416, Sigma-
Aldrich) horseradish peroxidase–conjugate antibody was
use at 1:2000 dilution. The antibody complexes were
detected by chemiluminescence by using Pierce ECL West-
ern Blotting Substrate (Thermo Fisher Scientific).
Preparation and Sequencing of Wild-Type and
S80Ki Whole-Liver RNA Samples
RNA was isolated from WT and S80A Knockin control
and peak fibrosis (4 weeks CCl4) whole livers. RNA
sequencing libraries were created by using Illumina (San
Diego, CA) TruSeq stranded mRNA kit. The sequencing was
single-end with 75-basepair read length, performed on
NextSeq 500 (Illumina) by using a high-output, 75-cycle
flow cell, providing >40 million reads per sample.
Transcript Quantification and Differential
Expression Analysis
Sequencing quality was assessed by FastQC software
(Available online at http://www.bioinformatics.babraham.ac.
uk/projects/fastqc/). Poor-quality bases and adaptors were
trimmed using Trimmomatic software,5 allowing a maximum
of 1 mismatch and a quality threshold of 20. The quasi-map-
ping mode of Salmon6 was used for the mapping and quan-
tification of the transcripts. The DESeq2 R package7 was used
to adjust the read counts by scaling a normalized factor in all
libraries and to assess the differential expression of the 2
treatments. The P values were corrected by the Benjamini and
Hochberg method8; then, the expression level was considered
significantly different at P adjusted of <.05 and log2 fold
change of >1. Plots were created with gplots R package. The
genes with significantly different expression levels as selected
by R were input into the IPA tools (http://www.qiagenbio
informatics.com/products/ingenuity-pathwayanalysis/) for
functional annotation.
Microarray and Computational Analysis
RNAwaspurified fromtotalRNAafter removalof ribosomal
RNA (mRNA-ONLY Eukaryotic mRNA Isolation Kit; Epicentre
Bio, Madison, WI). Each sample was amplified and transcribed
into fluorescent complementary RNA along the entire length of
the transcripts without 30 bias by using a random priming
method. The labeled complementaryRNAswere purified, and1
mgof each labeledcomplementaryRNAwashybridizedonto the
Mouse LncRNAArray v2.0 (8 60,000, Arraystar) for 17 hours
at 65C in an Agilent (Santa Clara, CA) Hybridization Oven. A
total of 25,376 protein-coding RNAs and 31,423 lncRNAs in the
mouse genomewere collected from themost authoritative data
sources, including RefSeq, University of California–Santa Cruz
Knowngenes, Ensembl, and related literature. After the slides
were washed, the arrays were scanned by the Agilent DNA
Microarray Scanner (part no. G2505C). The acquired array
images were analyzed by Agilent Feature Extraction software,
version 11.0.1.1. Quantile normalization and subsequent data
processing were performed with the GeneSpring GX, version
11.5.1, software package (Agilent). Differentially expressed
lncRNAs andmRNAswith statistical significance between the 2
groups were identified through volcano plot filtering. Gene
Ontology and Pathway analyses were performed in the stan-
dard enrichment computation method. The Integrative Geno-
mics Viewer (https://igv.org/app) was used to visualize and
interactively explore the location and organization within the
mouse genome of the differentially expressed lncRNAs and
their associated protein-coding genes.9,10 Predicted secondary
structures from lncRNA sequences were obtained using the
CentroidFold software, (available online at http://www.ncrna.
org/software/centroidfold/) and applying the CONTRAfold
model to calculate base-paring probabilities with 22 gamma
parameter to control the specificity and sensitivity of predicted
base pairs.11,12 Genes with expression levels that were
considered significantly different were input into the IPA tools
(http://www.qiagenbioinformatics.com/products/ingenuity-
pathwayanalysis/) for functional annotation.
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Supplementary Figure 1.One of the networks of differentially expressed focus genes formed by IPA. Blue nodes signify that a
gene was down-regulated in MeCP2–/y fibroblasts; red indicates up-regulation. Symbol shapes signify the nature of the
encoded protein, and unshaded symbols signify genes relevant to the pathway but not differentially expressed in our data set.
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Supplementary Figure 2. Another network of differentially expressed focus genes formed by IPA. Blue nodes signify that a gene
was down-regulated in MeCP2–/y fibroblasts; red indicates up-regulation. Symbol shapes signify the nature of the encoded
protein, and unshaded symbols signify genes relevant to the pathway but not differentially expressed in our data set.
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Supplementary Figure 3. (A) mRNA levels of Has2, Myl7,
desmin (Des), and aggrecan (Acan) as down-regulated genes
and (B) Cdk15, Tnxb, Sepp1, and Osnt as up-regulated genes
were quantified by qRT-PCR to validate the results of
microarray. Error bars in relevant panels represent mean ±
SEM. Statistical significance was determined by Student
t test; *P < .05, **P < .01. RLTD, relative level of transcrip-
tional difference.
Supplementary Figure 4. (A) mRNA level of Mcm6-2 quan-
tified by qRT-PCR to validate the results of microarray. (B, C)
mRNA levels of Pold1, Dna2, Rpa2, Eme1, Brip1, and Rad51
quantified by qRT-PCR to validate the results of microarray.
Error bars in relevant panels represent mean ± SEM. Statis-
tical significance was determined by Student t test; *P < .05,
**P < .01. KO, knockout; RLTD, relative level of transcriptional
difference.
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Supplementary
Figure 5. Identification/
representation of the
down-regulated transcript
uc008hgf as in close
physical association with
the ACTA2 (a-SMA) locus.
mRNA levels of
uc008hgf.1 and a-SMA
quantified by qRT-PCR to
validate the results of
microarray. Predicted RNA
secondary structures from
uc008hgf.1 lncRNA ob-
tained with CentroidFold
software using the CON-
TRAfold model. Error bars
in relevant panels repre-
sent mean ± SEM. Statis-
tical significance was
determined by Student t
test; *P < .05.
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Supplementary Figure 6.Graphical view of differentially expressed coding-noncoding gene coexpression network analysis
represents similar patterns of expression and interconnectivity of the most representative Gene Ontology terms (cell
cycle, DNA metabolic process, innate immunity, and protein activation cascades). The interaction network was produced in
Cytoscape, where nodes correspond to mRNA (triangles in purple) or lncRNA (circles in green), and the edges are the
coexpression links.
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Supplementary Figure 7. HSCs were isolated from 3 control and 3 MeCP2S80AKi mice, seeded at equal density at the start of
the experiment (day 0), and allowed to transdifferentiate in vitro. Photomicrographs were taken on days 1, 2, 3, 4, 6, and 8.
Representative pictures from all 3 lines from WT and MeCP2S80AKi are shown.
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Supplementary
Figure 8. (A) Western blot
for MeCP2 in whole liver or
activated HSCs; MeCP2
WT and KO brain was
used as positive or nega-
tive control, respectively.
(B) Liver–to–body weight
ratio in WT and MeC-
P2S80A mice treated with
chronic CCl4 or vehicle.
Error bars in relevant
panels represent mean ±
SEM. ***P < .001. (C)
Assessment of serum
transaminases alanine
transaminase (ALT) and
aspartate transaminase
(AST). KO, knockout.
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